WEEKLY e-ALERT  [ BASIC EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Case Studies
Xian Janssen: Embrace Better Future with New Solutions(11/19/2019 )  (Premium)
Editor´s Picks
CNIPA Issued Regulations On Collective Patent Examination(11/21/2019 )  (Premium)
Guidelines For Patent Examination Amended: Divisional, GUI, Subject Matter, Delayed Examination And So On(11/21/2019 )  (Premium)
The Market
Chinese Non-prescription Drug Sales Set to Reach CNY 250B by 2020(11/20/2019 )  (Premium)
Chinese Import of Medicines Up Only 1.6% in 3Qs/2019(11/18/2019 )  (Premium)
Industry News
MIIT Announces 2nd Batch of Centralized Manufacturing Centers for Shortage Drugs(11/21/2019 )  (Premium)
56 Listed Chinese Pharma Cos Had R&D Spending Above CNY 100M in 3Qs/2019(11/21/2019 )  (Premium)
Csafe Opens Shanghai Service Center For Pharma Containers(11/21/2019 )  (Premium)
Ascentage Breaks Ground on Its Global HQ, R&D Center and Manufacturing Facility in Suzhou(11/21/2019 )  (free)
Real Can Pharma and Zheshang Bank in Supply Chain Finance Blockchain(11/21/2019 )  (Premium)
Fosun Pharma, MimiVax to Jointly Develop and Commercialize SurVaxM Therapy in U.S.(11/21/2019 )  (Premium)
WuXi STA Forms Strategic Partnership with Impact Therapeutics(11/20/2019 )  (Premium)
Mundipharma Accused of Using Fake Doctors, Misleading Claims to Drive OxyContin Sales(11/20/2019 )  (Premium)
WuXi AppTec's LTD Expands Toxicology Facility in China(11/19/2019 )  (Premium)
Novartis Closes Early Drug Discovery R&D Unit in China(11/18/2019 )  (Premium)
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 As First Project(11/18/2019 )  (Premium)
Listed Chinese MedPharm Companies Report Slower Growth in Q3(11/18/2019 )  (Premium)
CNMA Publishes 2019 Top 100 OTC Drug Manufacturer Ranking(11/18/2019 )  (Premium)
General Health
NHC Issues Mobile Inspection Plan for Large Hospitals Between 2019 and 2022(11/21/2019 )  (Premium)
State Council Orders Prioritized Purchase of GQCE Essential Drugs with Large Price Gaps between Originator and Generic Drugs(11/20/2019 )  (Premium)
Legal/IPR News
Senate Report Accuses China of Technology Theft(11/21/2019 )  (Premium)
Northeast Pharma under Anti-monopoly Investigation in Liaoning(11/20/2019 )  (Premium)
Product/R&D News
NMPA Approves IND Application of MDI for Analgesic Penthrox(11/21/2019 )  (Premium)
LIDDS licensee Jiangxi Puheng Pharma Prepares for Phase III Trial in China(11/20/2019 )  (free)
© Wicon International GroupˇˇSupport by: www.heightow.com Home | Site map | Contact Us | Links